Эта страница была переведена автоматически, точность перевода не гарантируется. Пожалуйста, обратитесь к английской версии для исходного текста.

Исследование терапии гуселкумабом и ингибитором интерлейкина-17 (IL-17) у участников с псориатическим артритом в повседневной клинической практике (PsABIOnd)

2 ноября 2026 г. обновлено: Janssen Pharmaceutica N.V., Belgium

Оценка терапии Гуселкумабом (Тремфья) и ингибитором ИЛ-17 у пациентов с псориатическим артритом в рутинной клинической практике; Проспективное обсервационное когортное исследование

The purpose of this study is to evaluate treatment persistence with guselkumab and interleukin-17 inhibitor (IL-17i) initiated at enrollment into this study (PsABIOnd).

Обзор исследования

Статус

Активный, не рекрутирующий

Условия

Вмешательство/лечение

Подробное описание

Psoriatic arthritis (PsA) is a seronegative inflammatory spondylarthritis associated with psoriasis (PsO), which can cause pain and swelling in the joints, sausage-shaped swelling of the fingers and toes (dactylitis), inflammation of the muscle- or tendon insertions at adjacent bone (enthesitis), as well as raised red patches or various other expressions of psoriasis on the skin. Guselkumab (TREMFYA) is a fully human immunoglobulin G1 lambda (IgG1) monoclonal antibody (mAb) that binds to the p19 subunit of human interleukin (IL) 23 with high specificity and affinity, blocking IL-23 binding. Binding of guselkumab to the IL-23p19 subunit blocks the subsequent binding of extracellular IL-23 to the cell surface IL-23 receptor, inhibiting IL-23 specific intracellular signaling and subsequent activation and cytokine production. Participants with confirmed diagnosis of PsA who are starting guselkumab or any marketed interleukin-17 inhibitor (IL-17i) as a first, second, third, or fourth line of PsA biologic therapy per standard clinical practice will be enrolled in the main study. The aim of main study is to document the use of guselkumab and approved IL-17i therapies in routine clinical practice in patients with PsA who are starting guselkumab or an IL-17i as a first, second, third, or fourth line of biologic disease-modifying antirheumatic drugs (bDMARD) therapy. The overall duration of the main study, including recruitment and follow-up, is expected to be about 6 years. Participants who are starting guselkumab or an IL-17i treatment per routine clinical practice in the main study, and who meet the selection criteria for both the main study and substudy, will be consecutively offered entry into the substudy (a select number) at the time of enrollment into the main study. The substudy aims to collect additional data, continuously or with increased frequency, on the impact of guselkumab or IL-17i on patient mood, physical activity, sleep disturbance, disease symptoms, and health-related quality-of-life (HRQoL). Total duration of the substudy will be approximately 26-30 weeks consisting of a pre-treatment period of up to 14 days before the first dose of guselkumab or IL-17i in the main study and a 24-week (plus [+] up to 4 weeks follow-up) observation period.

Тип исследования

Наблюдательный

Регистрация (Действительный)

1314

Контакты и местонахождение

В этом разделе приведены контактные данные лиц, проводящих исследование, и информация о том, где проводится это исследование.

Места учебы

      • Adelaide, Австралия, 5011
        • The Queen Elizabeth Hospital
      • Footscray, Австралия
        • Footscray Hospital, Western Health
      • St Leonards, Австралия, 2065
        • Royal North Shore Hospital
      • Graz, Австрия, 8036
        • LKH-Univ. Klinikum Graz
      • Linz, Австрия, 4021
        • Kepler Universitatsklinikum GmbH
      • Vienna, Австрия, 1090
        • Medizinische Universitaet Wien
      • Vienna, Австрия, A-1100
        • Evang. Krankenhaus Gemein. Betriebgesm. Mbh
      • Buenos Aires, Аргентина, C1199ABB
        • Hospital Italiano de Buenos Aires
      • Buenos Aires, Аргентина, C1221ADC
        • Hospital J. M. Ramos Mejía
      • Buenos Aires, Аргентина, C1015ABO
        • OMI
      • Córdoba, Аргентина, 5000
        • Hospital Cordoba
      • San Fernando, Аргентина, B1646
        • MR Medicina Reumatologica
      • Bruges, Бельгия, 8000
        • AZ Sint-Jan
      • Brussels, Бельгия, 1070
        • Hopital Erasme
      • Genk, Бельгия, 3600
        • Reumaclinic Genk-Hasselt
      • Leuven, Бельгия, 3000
        • UZ Leuven
      • Liège, Бельгия, 4000
        • CHU de Liège - Domaine Universitaire du Sart Tilman
      • Amberg, Германия, 92224
        • Praxis für Rheumatologie
      • Bayreuth, Германия, 95444
        • Rheuma-Praxis Bayreuth
      • Berlin, Германия, 12161
        • Rheumatologische Schwerpunktpraxis
      • Berlin, Германия, 13055
        • Rheumatologische Schwerpunktpraxis 1
      • Cologne, Германия, 51149
        • Krankenhaus Porz am Rhein
      • Düsseldorf, Германия, 40225
        • Universitatsklinikum Dusseldorf
      • Erfurt, Германия, 99096
        • Service Rheuma Erfurt
      • Frankfurt, Германия, 60590
        • Universitatsklinikum Frankfurt
      • Halle, Германия, 6128
        • Rheumapraxis Dr. Liebhaber
      • Hamburg, Германия, 22767
        • Rheumatologie im Struenseehaus
      • Hamburg, Германия, 22415
        • Praxis fur Klinische Studien und Praxis fur Orthopadie
      • Herne, Германия, 44649
        • Rheumazentrum Ruhrgebiet
      • Leipzig, Германия, 04109
        • Rheumatologische Praxis 1
      • Magdeburg, Германия, 39104
        • Rheumatologische Praxis
      • München, Германия, 81541
        • Praxiszentrum St. Bonifatius
      • Neubrandenburg, Германия, 17033
        • Praxis Thilo Klopsch
      • Püttlingen, Германия, 66346
        • Knappschaftsklinikum Saar GmbH Klinik für Rheumatologie
      • Ratingen, Германия, 40878
        • Rheumazentrum Ratingen
      • Templin, Германия, 17268
        • Rheumatologisch-immunologische Arztpraxis
      • Vogelsang-Gommern, Германия, 39245
        • Immunologisches Zentrum Vogelsang-Gommern GmbH
      • Athens, Греция, 10676
        • Evangelismos General Hospital of Athens
      • Athens, Греция, 11527
        • Laiko General Hospital of Athens
      • Athens, Греция, 11521
        • Athens Navy Hospital
      • Athens, Греция, 11527
        • General Hospital 'Gennimatas'
      • Athens, Греция, 11527
        • Hippokration General Hospital of Athens, B' Internal Medicine Clinic,
      • Ioannina, Греция, 45560
        • University Hospital of Ioannina
      • Pátrai, Греция, 263 32
        • 'Agios Andreas' General Hospital of Patras
      • Pátrai, Греция, 26500
        • University General Hospital of Rio Patras
      • Thessaloniki, Греция, 546 42
        • Ippokrateio Hospital
      • A Coruña, Испания, 15006
        • Hosp Univ A Coruna
      • Algeciras / Cadiz, Испания, 11207
        • Hosp. Punta de Europa
      • Barcelona, Испания, 08036
        • Hosp Clinic de Barcelona
      • Barcelona, Испания, 8035
        • Hosp Univ Vall D Hebron
      • Bilbao, Испания, 48013
        • Hosp. Univ. de Basurto
      • Córdoba, Испания, 14004
        • Hosp Reina Sofia
      • Granada, Испания, 18016
        • Complejo hospitalario de Granada
      • Madrid, Испания, 28041
        • Hosp. Univ. 12 de Octubre
      • Madrid, Испания, 28905
        • Hosp. Univ. de Getafe
      • Oviedo, Испания, 33011
        • Hosp. Univ. Central de Asturias
      • Santiago de Compostela, Испания, 15706
        • Hosp. Clinico Univ. de Santiago
      • Seville, Испания, 41013
        • Hosp. Virgen Del Rocio
      • Bari, Италия, 70124
        • Azienda Ospedaliero Universitaria Consorziale Policlinico di Bari
      • Campobasso, Италия, 86100
        • Ospedale Regionale Cardarelli-Università degli Studi del Mol
      • Catanzaro, Италия, 88100
        • Universita della Magna grecia
      • Florence, Италия, 50141
        • AOU Careggi
      • Naples, Италия, 80131
        • Azienda Ospedaliera Universitaria Federico II
      • Naples, Италия, 80131
        • Seconda Univesità degli Studi di Napoli, AOU
      • Palermo, Италия, 90127
        • Azienda Ospedaliero Universitaria Policlinico Paolo Giaccone
      • Pisa, Италия, 56126
        • Azienda Ospedaliero Universitaria Pisana
      • Potenza, Италия, 85100
        • Ospedale San Carlo Di Potenza - Azienda Ospedaliera Regionale
      • Rome, Италия, 20123
        • Universita Cattolica del Sacro Cuore
      • Rozzano, Италия, 20156
        • Istituto Clinico Humanitas
      • Torino, Италия, 10126
        • Azienda Ospedaliera Città della Salute e della Scienza di Torino
      • Udine, Италия, 33100
        • Azienda Ospedaliero Universitaria S.Maria Della Misericordia
      • Verona, Италия, 37067
        • Azienda Ospedaliera Universitaria Integrata Verona
    • British Columbia
      • Vancouver, British Columbia, Канада, V5Z 1J9
        • Artus Health Centre
    • Manitoba
      • Winnipeg, Manitoba, Канада, R3A 1M3
        • Manitoba Clinic
    • Newfoundland and Labrador
      • St. John's, Newfoundland and Labrador, Канада, A1C 5B8
        • St. Claire's Mercy Hospital - Rheumatology Research
    • Nova Scotia
      • Coxheath, Nova Scotia, Канада, B1L 1B3
        • Dr. Juris Lazovskis Incorporated
    • Ontario
      • Dundas, Ontario, Канада, L9H 1B7
        • Private Practice - Dr. Pauline Boulos
      • Markham, Ontario, Канада, L3R 2C7
        • Markham Rheumatology Hub
      • Mississauga, Ontario, Канада, L5A 3V8
        • Brandusa Florica Medicine Professional Corporation
      • Orillia, Ontario, Канада, L3V 1T5
        • The Waterside Clinic
      • Ottawa, Ontario, Канада, K1H 7W9
        • The Ottawa Hospital Research Institute
      • Windsor, Ontario, Канада, N8X 1T3
        • Dr Sabeen Anwar Medicine Professional Corporation
    • Quebec
      • Montreal, Quebec, Канада, H1T 2M4
        • CIUSSS de l Est de l Ile de Montreal Installation Hopital Maisonneuve Rosemont
      • Québec, Quebec, Канада, G1V 4K5
        • G R M O Groupe de recherche en maladies osseuses Inc
      • Rimouski, Quebec, Канада, G5L 5T1
        • Centre de sante et services sociaux (CSSS) de Rimouski-Neigette - Hopital regional - Rimouski
      • Trois-Rivières, Quebec, Канада, G9A 3X2
        • Centre de Recherche Musculo Squelettique
    • Saskatchewan
      • Saskatoon, Saskatchewan, Канада, S7K 0H6
        • Community Rheumatology Care
      • Saskatoon, Saskatchewan, Канада, S7K 0H6
        • Rheumatology Associates of Saskatoon
      • Bogotá, Колумбия
        • BIOMAB
      • Bucaramanga, Колумбия
        • Servimed S A S
      • Medellín, Колумбия, 50012
        • Clinisalud del Sur
      • Medellín, Колумбия, 50025
        • Clinica Vascular las Americas
      • Montería, Колумбия, 230002
        • Funcentra
      • Mérida, Мексика, 97070
        • Medical Care & Research SA de CV
      • México, Мексика, 07760
        • Consultorio de Reumatologia
      • Zapopan, Мексика, 45116
        • Hospital Puerta de Hierro
      • Amsterdam, Нидерланды, 1105 AZ
        • Academisch Medisch Centrum Universiteit van Amsterdam
      • Enschede, Нидерланды, 7500 KA
        • Medisch Spectrum Twente
      • Groningen, Нидерланды, 9700 RB
        • Universitair Medisch Centrum Groningen
      • Helmond, Нидерланды, 5707 HA
        • Elkerliek Ziekenhuis
      • Kemerovo, Россия, G4 0SF
        • SBEU HPE Kemerovo State Medical Academy
      • Moscow, Россия, 121552
        • Bakoulev Scientific Center For Cardiovascular Surgery Rams
      • Moscow, Россия, 190068
        • FGBU Research Institute of Rheumatology named V.A.Nasonova
      • Tomsk, Россия, 634045
        • City Hospital #3
      • Aberdeen, Соединенное Королевство, AB25 2ZB
        • NHS Grampian - Aberdeen Royal Infirmary (ARI)
      • Abergavenny, Соединенное Королевство, NP7 7EG
        • Nevill Hall Hospital
      • Airdrie, Соединенное Королевство, ML6 0JS
        • University Hospital Monklands
      • Barnet, Соединенное Королевство, EN5 3DJ
        • Royal Free London NHS Foundation Trust Barnet Hospital
      • Bath, Соединенное Королевство, BA1 3NG
        • Wolfson Centre Royal United Hospitals
      • Glasgow, Соединенное Королевство, 650029
        • Glasgow Royal Infirmary
      • Hull, Соединенное Королевство, HU3 2JZ
        • Hull Royal Infirmary
      • Leeds, Соединенное Королевство, LS7 4SA
        • Leeds Teaching Hospitals NHS Trust Chapel Allerton Hospital
      • Manchester, Соединенное Королевство, M13 9WL
        • Central Manchester University Hospitals NHS Foundation Trust
      • Newcastle upon Tyne, Соединенное Королевство, NE7 7DN
        • The Newcastle upon Tyne Hospitals NHS Trust - Freeman Hospit
      • Portsmouth, Соединенное Королевство, PO6 3LY
        • Queen Alexandra Hospital
      • Salford, Соединенное Королевство, M6 8HD
        • Shirley Caldwell
      • Southampton, Соединенное Королевство, SO16 6YD
        • Southampton General Hospital
      • Staffordshire, Соединенное Королевство, ST6 7AG
        • Haywood Hospital
      • Stamford, Соединенное Королевство, PE9 1UA
        • Stamford and Rutland hospital
      • Wishaw, Соединенное Королевство, ML2 0DP
        • Wishaw General
      • Kaohsiung City, Тайвань, 81362
        • Kaohsiung Veterans General Hospital
      • Kaohsiung City, Тайвань, 83301
        • Chang Gung Medical Foundation
      • Taichung, Тайвань
        • Taichung Veterans General Hospital
      • Bobigny, Франция, 93000
        • Hôpital Avicenne
      • Cholet, Франция, 49300
        • Centre Hospitalier de Cholet
      • Clermont-Ferrand, Франция, 63003
        • Hôpital Gabriel Montpied
      • Créteil, Франция, 94000
        • Centre Hospitalier Universitaire(CHU) - Hopital Henri Mondor
      • Lille, Франция, 59037
        • CHRU HOPITAL ROGER SALENGRO Consultation Appareil locomoteur
      • Lyon, Франция, 69008
        • Centre Orthopedique Santy
      • Lyon, Франция, 69300
        • Clinique de l'Infirmerie Protestante de Lyon
      • Nice, Франция, 6006
        • Hôpital Saint Roch
      • Orléans, Франция, 45032
        • CHR Orléans - Nouvel Hôpital Orléans La Source
      • Paris, Франция, 75018
        • Hôpital Bichat
      • Paris, Франция, 75010
        • Hôpital Lariboisière - Centre Viggo Petersen
      • Paris, Франция, 75012
        • Hopital Saint-Antoine
      • Paris, Франция, 75651
        • Hopital Pitie Salpetriere
      • Strasbourg, Франция, 67098
        • CHRU Hôpital de Hautepierre
      • Toulouse, Франция, 31059
        • Hopital Purpan
      • Échirolles, Франция, 38130
        • CHU Grenoble
      • Fribourg, Швейцария, 1708
        • HFR Fribourg - Hôpital Cantonal
      • Gothenburg, Швеция, 41345
        • Sahlgrenska Universitetssjukhuset
      • Malmö, Швеция, 20502
        • Universitetssjukhuset i Lund
      • Stockholm, Швеция, 113 65
        • Akademiskt Specialistcentrum centrum för reumatologi
      • Uppsala, Швеция, 75185
        • Akademiska Sjukhuset
      • Örebro, Швеция, 70185
        • Universitetssjukhuset Orebro
      • Cheonan-si, Южная Корея, 31151
        • Soonchunhyang University Cheonan Hospital
      • Seongnam, Южная Корея, 13620
        • Seoul National University Bundang Hospital
      • Seoul, Южная Корея, 03080
        • Seoul National University Hospital
      • Seoul, Южная Корея, 07061
        • Seoul Metropolitan Government Seoul National University Boramae Medical Center
      • Hyōgo, Япония, 6751392
        • Kita-harima Medical Center
      • Meguro-ku, Япония, 153-8515
        • Toho University Medical Center, Ohashi Hospital
      • Osaka, Япония, 550 0006
        • Public Interest Incorporated Foundation Nipoon Life Saiseikai Nippon Life Hospital
      • Osaka, Япония, 545 8586
        • Osaka Metropolitan University Hospital
      • Sapporo, Япония, 060-8648
        • Hokkaido University Hospital
      • Tokyo, Япония, 181 8611
        • Kyorin University Hospital

Критерии участия

Исследователи ищут людей, которые соответствуют определенному описанию, называемому критериям приемлемости. Некоторыми примерами этих критериев являются общее состояние здоровья человека или предшествующее лечение.

Критерии приемлемости

Возраст, подходящий для обучения

18 лет и старше (Взрослый, Пожилой взрослый)

Принимает здоровых добровольцев

Н/Д

Полы, имеющие право на обучение

Все

Метод выборки

Невероятностная выборка

Исследуемая популяция

The study population consists of participants initially treated for Psoriatic Arthritis (PsA) with guselkumab or interleukin-17 inhibitor (IL-17i) per routine clinical practice in accordance with clinical guidelines.

Описание

Inclusion Criteria:

Main study:

  • Have a confirmed diagnosis of PsA as determined by a rheumatologist with reference to Classification criteria for Psoriatic Arthritis (CASPAR)
  • Start guselkumab or any approved interleukin-17 inhibitor (IL-17i) as a first, second, third, or fourth line of biologic disease-modifying antirheumatic drugs (bDMARD) therapy for the indication of PsA as part of standard clinical practice (according to local label, local regulations, and/or reimbursement requirements) at the time of enrollment into the observational study or within a maximum of 2 months after the initial baseline visit or after repeated baseline data collection
  • Sign a participation agreement/Informed consent form (ICF) allowing data collection and source data verification in accordance with local requirements
  • Able to read, understand, and intend to comply with completion of all Electronic patient-reported outcome (ePRO) instruments
  • The treatment decision must be taken by the participating rheumatologist prior to, and independently of the participant's inclusion into the study, following clinical practice in accordance with local and overarching guidelines and local regulations

Substudy:

  • Must sign the substudy ICF allowing data collection in accordance with local requirements
  • Is scheduled to receive guselkumab or IL-17i, per routine clinical practice, in the main study
  • Currently using or is willing to use wearables and/or commercial applications to track their disease within the course of their normal daily activities

Exclusion Criteria:

Main study:

  • Start guselkumab or an IL-17i therapy as fifth or further line of biologic treatment
  • Have already taken a specific IL-17i or IL-23i treatment and are planning on re-taking that specific treatment again
  • Unwilling or unable to participate in long-term data collection
  • Received an investigational drug (including investigational vaccines) or used an invasive investigational medical device within 30 days before the start of the study (that is, signing of informed consent)
  • Currently enrolled in any interventional study or any Janssen-sponsored observational clinical study (contemporary participation into observational studies or registries not sponsored by Janssen is acceptable)

Substudy:

  • Have an insufficient command of language to interact effectively with the smartphone application, in the opinion of the investigator at each site
  • Any condition for which, in the opinion of the investigator, participation would not be in the best interest of the patient (example, compromise the well-being) or that could prevent, limit, or confound assessment
  • Unwilling or unable to comply with substudy assessments

Учебный план

В этом разделе представлена ​​подробная информация о плане исследования, в том числе о том, как планируется исследование и что оно измеряет.

Как устроено исследование?

Детали дизайна

  • Наблюдательные модели: COHORT
  • Временные перспективы: PROSPECTIVE

Когорты и вмешательства

Группа / когорта
Вмешательство/лечение
Cohort 1: Guselkumab

Data as available from participant's source medical records will be collected for adult participants with a confirmed diagnosis of Psoriatic Arthritis (PsA) who are starting guselkumab as a first, second, third, or fourth line of PsA biologic therapy either as monotherapy or with other medications per routine clinical practice in main study. Participants who meet the selection criteria for both the main study and substudy, will be consecutively offered to be enrolled into the substudy at the time of enrollment into the main study.

Participants will not receive any intervention as a part of this study. Participants who are initiating the treatment with guselkumab, will be observed according to standard clinical practice.

Другие имена:
  • ТРЕМФЯ
Cohort 2: Interleukin-17 inhibitor (IL-17i)

Data as available from participant's source medical records will be collected for adult participants with a confirmed diagnosis of PsA who are starting IL-17i as a first, second, third, or fourth line of PsA biologic therapy either as monotherapy or with other medications per routine clinical practice in main study. Participants who meet the selection criteria for both the main study and substudy, will be consecutively offered to be enrolled into the substudy at the time of enrollment into the main study.

Participants will not receive any intervention as a part of this study. Participants who are initiating the treatment with IL-17i, will be observed according to standard clinical practice.

Что измеряет исследование?

Первичные показатели результатов

Мера результата
Мера Описание
Временное ограничение
The Start and Stop Date of Guselkumab, as Applicable, For Each Participant
Временное ограничение: Up to 39 months

The start and stop date, (first and last administration date, respectively) of guselkumab, as applicable, for each participant will be collected to document treatment persistence.

Up to 39 months
The Start and Stop Date of Interleukin-17 Inhibitor (IL-17i), as Applicable, For Each Participant
Временное ограничение: Up to 39 months

The start and stop date (first and last administration date respectively) of IL-17i, as applicable, for each participant will be collected to document treatment persistence.

Up to 39 months

Вторичные показатели результатов

Мера результата
Мера Описание
Временное ограничение
Change from Baseline in 66 and 68 Joint Counts for Swelling and Tenderness, Respectively
Временное ограничение: Baseline up to 39 months

Change from baseline in 66 and 68 joint counts for swelling and tenderness, respectively will be reported. Joints assessed include the distal interphalangeal, proximal interphalangeal, and metacarpophalangeal joints of the hands; the wrist, elbow, shoulder, acromioclavicular, sternoclavicular, temporomandibular, hip (excluded for swelling), knee, ankle, and midtarsal joints; and the metatarsophalangeal and proximal interphalangeal joints of the feet.

Baseline up to 39 months
Change from Baseline in Rheumatologist's Global Assessment of Disease Activity-Psoriatic Arthritis (PGA-PsA)
Временное ограничение: Baseline up to 39 months

The PGA-PsA will be documented using a Visual Analogue Scale (VAS) that ranges from "no PsA activity" (0 Millimeter [mm]) to "extremely active PsA" (100 mm).

Baseline up to 39 months
Change from Baseline in Assessment of Dactylitis
Временное ограничение: Baseline up to 39 months

The presence of and total number of digits of the hands and feet (that is, 0 to 20) with dactylitis will be documented.

Baseline up to 39 months
Change from Baseline in Assessment of Enthesitis using Leeds Enthesitis Index (LEI)
Временное ограничение: Baseline up to 39 months

The presence and a score of enthesitis will be documented using the LEI to evaluate the presence (score of 1) or absence (score of 0) of pain by applying local pressure to the following entheses: the lateral epicondyles (left and right), medial femoral condyles (left and right), and Achilles tendon insertions (left and right).

Baseline up to 39 months
Change from Baseline in Nail Involvement
Временное ограничение: Baseline up to 39 months

Nail involvement will be documented by recording the total number of nails of the hands and feet (that is, 0 to 20) with psoriatic nail changes.

Baseline up to 39 months
Change from Baseline in Body Surface Area (BSA) Psoriasis (PSO) Skin Involvement
Временное ограничение: Baseline up to 39 months

The BSA score indicates the surface area of the participant's body effected by psoriasis.

Baseline up to 39 months
Change from Baseline in C-reactive Protein (CRP)
Временное ограничение: Baseline up to 39 months

Change from baseline in CRP will be reported.

Baseline up to 39 months
Change from Baseline in Minimal Disease Activity (MDA)/ Very Low Disease Activity (VLDA)
Временное ограничение: Baseline up to 39 months

Change from Baseline in MDA/VLDA will be reported.

Baseline up to 39 months
Change from Baseline in Clinical Disease Activity Index for Psoriatic Arthritis (cDAPSA/DAPSA)
Временное ограничение: Baseline up to 39 months

DAPSA assesses the joint domain of PsA and is derived from the sum of the following components: Participant's assessment of pain on VAS (in centimeters), Participant's Global Assessment of Disease Activity on VAS (in centimeters), 66 and 68 joint counts for swelling and tenderness, respectively.

Baseline up to 39 months
Response as a Measure of Clinical Improvement in cDAPSA/DAPSA
Временное ограничение: Up to 39 months

Response is defined as a clinical improvement in cDAPSA/DAPSA. DAPSA assesses the joint domain of PsA and is derived from the sum of the following components: Participant's assessment of pain on VAS (in centimeters), Participant's Global Assessment of Disease Activity on VAS (in centimeters), 66 and 68 joint counts for swelling and tenderness, respectively.

Up to 39 months
Start and Stop Dates of All Treatments and the Sequence of Treatment Lines
Временное ограничение: Up to 39 months

Start and stop dates of all treatments and the sequence of treatment lines will be reported.

Up to 39 months
Percentage of Participants with Adverse Events (AEs)
Временное ограничение: Up to 39 months

An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study.

Up to 39 months
BSA PSO Skin Involvement
Временное ограничение: Up to 39 months

The BSA score indicates the surface area of the participant's body affected by psoriasis.

Up to 39 months
Rheumatic Disease Comorbidity Index
Временное ограничение: Up to 39 months

Number of comorbid medical conditions of the study participants for the Rheumatic Disease Comorbidity Index will be reported.

Up to 39 months
Change from Baseline in Fibromyalgia Rapid Screening Tool (FiRST)
Временное ограничение: Baseline up to 6 months

FiRST will be used to help determine whether participants have chronic widespread pain or fibromyalgia syndrome at entry into the study. The FiRST is a validated questionnaire consisting of a combination of 6 items that can detect chronic widespread pain.

Baseline up to 6 months
Change from Baseline in European Quality of Life (EuroQoL) 5-Dimensions 5-Levels Questionnaire (EQ-5D-5L)
Временное ограничение: Baseline up to 39 months

The EQ-5D-5L is a standardized instrument for use as a measure of health outcome, primarily designed for self-completion by respondents. The EQ-5D-5L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each of the 5 dimensions is divided into 5 levels of perceived problems, where Level 1: no problem, Level 2: slight problems, Level 3: moderate problems, Level 4: severe problems and Level 5: extreme problems.

Baseline up to 39 months
Change from Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI)
Временное ограничение: Baseline up to 39 months

The functional status of the participants will be assessed by the HAQ-DI. This 20-question self-administered instrument assesses the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). The derived HAQ-DI ranges from 0, indicating no difficulty, to 3, indicating inability to perform a task in that area.

Baseline up to 39 months
Change from Baseline in Psoriatic Arthritis Impact of Disease-12 (PsAID-12)
Временное ограничение: Baseline up to 39 months

PsAID-12 is a validated, self-administered questionnaire that assesses the impact of PsA on participants' lives. It consists of 12 questions, each answered using a numerical rating scale. Questions related to pain, skin problems, work and/or leisure activities, discomfort, embarrassment and/or shame, social participation, and anger, fear, and uncertainty, and depression are scored from 0 (none) to 10 (extreme), functional capacity and sleep disturbance are scored from 0 (no difficulty) to 10 (extreme difficulty) and coping is scored from 0 (very well) to 10 (very poorly).

Baseline up to 39 months
Change from Baseline in Patient Global Disease Activity Visual Analog Scale (VAS) Scores
Временное ограничение: Baseline up to 39 months

The Patient Global Disease Activity VAS is a self-administered assessment with scores ranging from "very well" (0 mm) to "very poor" (100 mm) that assesses disease activity over the past week.

Baseline up to 39 months
Change from Baseline in Pain VAS Score
Временное ограничение: Baseline up to 39 months

The pain VAS is a self-administered assessment of average pain during the past week. The scale ranges from "no pain" (0 mm) to "the worst possible pain" (100 mm).

Baseline up to 39 months
Change from Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)
Временное ограничение: Baseline up to 39 months

BASDAI consists of a 1 through 10 scale (1 being no problem and 10 being the worst problem) which is used to answer 6 questions pertaining to the 5 major symptoms of ankylosing spondylitis: fatigue, spinal pain, joint pain/swelling, areas of localized tenderness (also called enthesitis, or inflammation of tendons and ligaments), morning stiffness duration, morning stiffness severity.

Baseline up to 39 months
Change from Baseline in Ankylosing Spondylitis Disease Activity Score - C-reactive protein (ASDAS-CRP)
Временное ограничение: Baseline up to 39 months

The ASDAS-CRP is a composite of 5 disease activity variables with only partial overlap. The 4 self-reported items included in this index are back pain (VAS), duration of morning stiffness, peripheral pain/swelling, and participant global assessment of disease activity; these are combined with the CRP value.

Baseline up to 39 months
Change from Baseline in Dermatology Life Quality Index (DLQI)
Временное ограничение: Baseline up to 39 months

The DLQI is a dermatology-specific, validated, 10-question quality of life instrument used to measure the impact of skin disease on the quality of life of an affected person. Each question will address how much the participant's skin problem has affected their life and is scored as: 3 = very much, 2 = a lot, 1 = a little, 0 = not at all, or not relevant.

Baseline up to 39 months
Change from Baseline in Patient Acceptable Symptom State (PASS)
Временное ограничение: Baseline up to 39 months

The PASS measures the level of symptoms beyond which participants consider themselves well. The PASS addresses the concepts of low disease activity, partial remission in symptoms, and well-being.

Baseline up to 39 months
Change from Baseline in Work Productivity and Activity Impairment Questionnaire: Psoriatic Arthritis (WPAI: PsA)
Временное ограничение: Baseline up to 39 months

The WPAI: PsA is a validated, self-administered questionnaire that assesses work and activity impairment during the past 7 days. The WPAI: PsA produces 4 types of scores: absenteeism (work time missed), presenteeism (impairment at work/reduced on-the-job effectiveness), work productivity loss (overall work impairment/absenteeism plus presenteeism), and activity impairment. The WPAI: PsA outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity, that is, worse outcomes.

Baseline up to 39 months
Change from Baseline in Treatment Satisfaction Questionnaire for Medication-9 (TSQM-9)
Временное ограничение: Baseline up to 39 months

TSQM-9 is a 9-item, validated, self-administered instrument used to assess participant's satisfaction with medication. The three domains assessed are effectiveness, convenience, and side effects of the medication.

Baseline up to 39 months
Number of Participants Switching or Stopping Treatment
Временное ограничение: Up to 39 months

Number of Participants switching or stopping treatment (including reasons for discontinuation) will be reported.

Up to 39 months

Соавторы и исследователи

Здесь вы найдете людей и организации, участвующие в этом исследовании.

Спонсор

Следователи

  • Директор по исследованиям: Janssen Pharmaceutica N.V., Belgium Clinical Trial, Janssen Pharmaceutica N.V., Belgium

Публикации и полезные ссылки

Лицо, ответственное за внесение сведений об исследовании, добровольно предоставляет эти публикации. Это может быть что угодно, связанное с исследованием.

Даты записи исследования

Эти даты отслеживают ход отправки отчетов об исследованиях и сводных результатов на сайт ClinicalTrials.gov. Записи исследований и сообщаемые результаты проверяются Национальной медицинской библиотекой (NLM), чтобы убедиться, что они соответствуют определенным стандартам контроля качества, прежде чем публиковать их на общедоступном веб-сайте.

Изучение основных дат

Начало исследования (Действительный)

25 августа 2021 г.

Первичное завершение (Оцененный)

1 августа 2027 г.

Завершение исследования (Оцененный)

2 августа 2027 г.

Даты регистрации исследования

Первый отправленный

31 августа 2021 г.

Впервые представлено, что соответствует критериям контроля качества

17 сентября 2021 г.

Первый опубликованный (Действительный)

20 сентября 2021 г.

Обновления учебных записей

Последнее опубликованное обновление (Действительный)

3 ноября 2026 г.

Последнее отправленное обновление, отвечающее критериям контроля качества

2 ноября 2026 г.

Последняя проверка

1 ноября 2026 г.

Дополнительная информация

Термины, связанные с этим исследованием

Другие идентификационные номера исследования

  • CR108938
  • CNTO1959PSA4001 (Другой идентификатор: Janssen Research & Development, LLC)

Планирование данных отдельных участников (IPD)

Планируете делиться данными об отдельных участниках (IPD)?

НЕТ

Информация о лекарствах и устройствах, исследовательские документы

Изучает лекарственный продукт, регулируемый FDA США.

Нет

Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .